135046-48-9 Usage
Description
Clopidogrel hydrogen sulfate is a colorless to light yellow liquid with antithrombotic properties, which is primarily used as a platelet aggregation inhibitor. It is a derivative of Clopidogrel and plays a crucial role in preventing blood clot formation, thus reducing the risk of heart attacks, strokes, and other cardiovascular events.
Uses
1. Used in Pharmaceutical Industry:
Clopidogrel hydrogen sulfate is used as an antithrombotic agent for preventing blood clot formation. It is particularly effective in reducing the risk of heart attacks, strokes, and other cardiovascular events by inhibiting platelet aggregation.
2. Used in Cardiology:
Clopidogrel hydrogen sulfate is used as a platelet aggregation inhibitor for patients with coronary artery disease, peripheral vascular disease, and those who have undergone coronary stenting or angioplasty. It helps in maintaining the patency of the blood vessels and preventing the recurrence of heart attacks.
3. Used in the Synthesis of Clopidogrel Derivatives:
Clopidogrel hydrogen sulfate is used in the synthesis of Clopidogrel derivatives, which are also platelet aggregation inhibitors. These derivatives can be used for the development of new drugs with improved efficacy and reduced side effects.
4. Used in Research and Development:
Clopidogrel hydrogen sulfate is used as a research compound for studying its antithrombotic properties and potential applications in the development of new drugs for the treatment of cardiovascular diseases.
Anti-platelet aggregation drug
Thrombosis caused by arterial atheromatous plaque leads to acute thrombosis cardiovascular and cerebrovascular events. In this pathogenesis, platelets play a central role, which has been fully studied.
Clopidogrel hydrogen sulfate is similar to ticlopidine, which is a new anti-platelet aggregation drug, successfully developed by French Sanofi-Synthelabo Fort for the prevention and treatment of heart, brain and other arterial circulation disorders caused by the high blood platelet aggregation, such as recent onset of stroke, myocardial infarction and patients diagnosed with peripheral arterial disease. Many countries have already used it, including United States, Europe and China. This product inhibited platelet activation by inhibiting adenosine diphosphate (ADP) pathway to inhibit platelet aggregation. Since clopidogrel hydrogen sulfate takes several days to achieve effective blood concentration, it does not apply to emergency treatment. Stop using 7 to 10 days, platelet function returned to normal state.
The above information is edited by the lookchem of Kui Ming.
Biochem/physiol Actions
Inhibits ADP-induced platelet aggregation; anti-thrombotic drug.
Check Digit Verification of cas no
The CAS Registry Mumber 135046-48-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,5,0,4 and 6 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 135046-48:
(8*1)+(7*3)+(6*5)+(5*0)+(4*4)+(3*6)+(2*4)+(1*8)=109
109 % 10 = 9
So 135046-48-9 is a valid CAS Registry Number.
InChI:InChI=1/C15H14ClNO2S.H2O4S/c16-12-4-2-1-3-11(12)14(15(18)19)17-7-5-13-10(9-17)6-8-20-13;1-5(2,3)4/h1-4,6,8,14H,5,7,9H2,(H,18,19);(H2,1,2,3,4)/t14-;/m0./s1
135046-48-9Relevant articles and documents
Efficient Synthesis of (S)-(+)-Clopidogrel Bisulfate-Capped Silver Nanoparticles
Mahmoodi, Nosrat O.,Ghavidast, Atefeh,Ashkan, Mitra,Mamaghani, Manouchehr,Zanjanchi, Mohammad Ali,Tabatabaeian, Khalil,Arabanian, Armin
, p. 1552 - 1557 (2016/06/09)
In this work primarily one-pot synthetic development in the preparation of clopidogrel bisulfate with a polymorphic crystalline form II in 90% yield was developed. This premade antiplatelet drug has been used to protect starch-stabilized silver nanoparticles (AgNPs).
PROCESS FOR THE PREPARATION OF POLYMORPHIC FORMS OF CLOPIDOGREL HYDROGEN SULFATE
-
Page/Page column 5, (2009/04/24)
The present invention relates to a novel process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate, namely methyl(+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate of formula (I). Particularly the present invention relates to the process for the preparation of form (I) and amorphous clopidogrel hydrogen sulfate.
Industrial process for preparation a polmorph of clopidogrel hydrogen sulphate
-
Page/Page column 10, (2008/06/13)
An improved process for the manufacture of Clopidogrel starting from 2-(2-thienyl) ethylamine, which eliminates the isolation of an unstable intermediate like 2-(2-thienyl) ethyl formimine by subjecting it to a one pot cyclization to get 4,5,6,7-tetrahydrothieno (3,2-c) pyridine of Formula II and further reacting with halo-compound of Formula III (where X is Cl or Br) at 20 to 90 °C temperature characterized in a solvent like water and/or dichloroethane in presence of organic or inorganic bases is disclosed herein. This invention further discloses a process for resolution of racemic clopidogrel into its optical antipodes and converting the dextroclopidogrel base into its known polymorphs namely 'Form I' or 'Form II' in solvents selected from methyl propyl ketone, methyl isopropyl ketone, diethyl ketone or their mixture thereof, mixture of ethyl acetate and methyl propyl ketone, mixture of ethyl acetate and methyl isopropyl ketone, or mixture of ethyl acetate and diethyl ketone or ethyl acetate.